STRYKER CORP: management transactions · United States · SEC (Form 4)

About STRYKER CORP

Stryker Corp. (ticker: SYK) is a leading U.S. healthcare company listed on the NYSE. Headquartered in Portage, Michigan, United States, the company is one of the major global players in medical technologies. Its roots go back to 1941, when Homer Stryker began developing and commercializing inventions inspired by his orthopedic practice. That origin still shapes the company’s identity today: product innovation, close collaboration with clinicians, and a disciplined acquisition strategy used to broaden its portfolio. ([stryker.com](https://www.stryker.com/us/en/about.html?utm_source=openai)) Stryker operates through three core reporting areas: MedSurg, Neurotechnology, and Orthopaedics. MedSurg includes surgical equipment, endoscopy, patient-handling and patient-safety technologies, and selected hospital care products. Neurotechnology covers neurosurgical and neurovascular solutions, as well as certain spine- and pain-related technologies. Orthopaedics comprises implants and solutions for hip, knee, shoulder, trauma, and extremities procedures. This structure gives Stryker a diversified exposure across hospital capital spending, elective surgery, and higher-value specialty procedures. ([stryker.com](https://www.stryker.com/us/en/about.html?utm_source=openai)) From a competitive standpoint, Stryker is widely regarded as a top-tier medical device leader, with strong brand recognition among hospitals and surgeons. Its positioning is built on clinical quality, a robust commercial footprint, and the ability to offer broad procedural platforms that combine instruments, implants, consumables, and adjacent digital solutions. The company has a meaningful global footprint, with revenue-generating operations across the United States, Europe, the Middle East and Africa, Asia Pacific, and other foreign markets, including Canada and Latin America. ([sec.gov](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/syk-20241231.htm?utm_source=openai)) Its product set spans surgical systems, hospital equipment, orthopedic implants, and newer solutions in thrombectomy, intravascular lithotripsy, and foot-and-ankle surgery. Recent corporate developments highlight an active M&A agenda and a continued push into faster-growing vascular categories: Stryker completed its acquisition of Inari Medical in February 2025, then used that platform to launch new products such as InThrill and Artix. In 2026, it announced and completed the acquisition of Amplitude Vascular Systems to strengthen its peripheral vascular portfolio. The company also secured FDA clearances for products such as OptaBlate BVN and Incompass, underscoring an active innovation pipeline. ([investors.stryker.com](https://investors.stryker.com/press-releases/news-details/2025/Stryker-completes-acquisition-of-Inari-Medical-Inc.-providing-entry-into-the-high-growth-peripheral-vascular-segment/default.aspx?utm_source=openai)) For investors, Stryker remains a high-quality U.S. healthcare name: defensive characteristics, recurring innovation, a large installed base, and consistent execution. The main considerations are exposure to hospital spending cycles, intense competition, and operational or cybersecurity risks given the scale and complexity of its technology-enabled business. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/01/28/3016762/0/en/Stryker-reports-2024-operating-results-and-2025-outlook.html?utm_source=openai))